{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse%2FRecurrence&page=83", "query": { "condition": "Relapse/Recurrence", "page": 83 }, "page_size": 10 }, "pagination": { "page": 83, "page_size": 10, "total_count": 3146, "total_pages": 315, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse%2FRecurrence&page=84&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse%2FRecurrence&page=82&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-10T07:09:07.244Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02230969", "title": "Plegridy Observational Program", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Relapsing Forms of Multiple Sclerosis" ], "interventions": [ { "name": "peginterferon beta-1a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1208, "start_date": "2014-11-12", "completion_date": "2022-01-20", "has_results": false, "last_update_posted_date": "2022-09-26", "last_synced_at": "2026-11-10T07:09:07.244Z", "location_count": 50, "location_summary": "Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 44 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "California City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02230969" }, { "nct_id": "NCT01082211", "title": "Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "3D-Conformal External Beam", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 65, "start_date": "2010-06", "completion_date": "2022-05-20", "has_results": true, "last_update_posted_date": "2022-06-21", "last_synced_at": "2026-11-10T07:09:07.244Z", "location_count": 57, "location_summary": "Peoria, Arizona • Burbank, California • Aurora, Colorado + 44 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlantis", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01082211" }, { "nct_id": "NCT06453044", "title": "Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3a Follicular Lymphoma", "Refractory Grade 1 Follicular Lymphoma", "Refractory Grade 2 Follicular Lymphoma", "Refractory Grade 3a Follicular Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mosunetuzumab", "type": "BIOLOGICAL" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2024-09-09", "completion_date": "2028-03-14", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-11-10T07:09:07.244Z", "location_count": 2, "location_summary": "Duarte, California • Irvine, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06453044" }, { "nct_id": "NCT00895934", "title": "Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "gemtuzumab ozogamicin", "type": "DRUG" }, { "name": "azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 52, "start_date": "2009-05", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2019-05-23", "last_synced_at": "2026-11-10T07:09:07.244Z", "location_count": 4, "location_summary": "Stanford, California • Bremerton, Washington • Seattle, Washington", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Bremerton", "state": "Washington" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00895934" }, { "nct_id": "NCT00481871", "title": "Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed or Refractory Lymphoproliferative Malignancies", "Hodgkin's Lymphoma", "Peripheral T-cell Lymphoma", "B-cell Lymphoma", "Waldenstrom's Macroglobulinemia" ], "interventions": [ { "name": "Pralatrexate Injection", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Vitamin B12", "type": "DIETARY_SUPPLEMENT" }, { "name": "Folic Acid", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Acrotech Biopharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 119, "start_date": "2007-05", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2020-01-07", "last_synced_at": "2026-11-10T07:09:07.244Z", "location_count": 15, "location_summary": "Los Angeles, California • Stanford, California • Denver, Colorado + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00481871" }, { "nct_id": "NCT05292664", "title": "Venetoclax Basket Trial for High Risk Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndromes, de Novo", "Myelodysplastic Syndromes, Secondary", "Myelodysplastic Syndromes, Previously Treated", "Treatment-Related Acute Myeloid Leukemia", "Therapy-Related Myelodysplastic Syndrome", "Acute Lymphoblastic Leukemia, in Relapse", "Acute Lymphoblastic Leukemia With Failed Remission", "Lymphoblastic Lymphoma, in Relapse", "Lymphoblastic Lymphoma, Refractory", "Acute Leukemia of Ambiguous Lineage in Relapse", "Acute Leukemia of Ambiguous Lineage" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Dexrazoxane", "type": "DRUG" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Erwinia asparaginase", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andrew E. Place, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "40 Years", "sex": "ALL", "summary": "1 Year to 40 Years" }, "enrollment_count": 30, "start_date": "2023-03-29", "completion_date": "2030-07-02", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-11-10T07:09:07.244Z", "location_count": 5, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05292664" }, { "nct_id": "NCT06079164", "title": "Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Large B-cell Lymphoma" ], "interventions": [ { "name": "KITE-197", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2023-11-09", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-11-10T07:09:07.244Z", "location_count": 5, "location_summary": "Miami, Florida • Chicago, Illinois • Nashville, Tennessee + 2 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Austin", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06079164" }, { "nct_id": "NCT01781728", "title": "Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Periampullary Adenocarcinoma" ], "interventions": [ { "name": "Stereotactic Body Radiation Therapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 48, "start_date": "2013-01-01", "completion_date": "2024-06-01", "has_results": true, "last_update_posted_date": "2025-07-20", "last_synced_at": "2026-11-10T07:09:07.244Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01781728" }, { "nct_id": "NCT00005787", "title": "Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Neutropenia" ], "interventions": [ { "name": "epoetin alfa", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "recombinant flt3 ligand", "type": "BIOLOGICAL" }, { "name": "recombinant interleukin-3", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "17 Years to 65 Years" }, "enrollment_count": 3, "start_date": "1999-09", "completion_date": "2002-01", "has_results": false, "last_update_posted_date": "2012-06-01", "last_synced_at": "2026-11-10T07:09:07.244Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005787" }, { "nct_id": "NCT05662306", "title": "C-Cog in Early Course Schizophrenia Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Aripiprazole Lauroxil", "type": "DRUG" }, { "name": "Computerized cognitive and functional skills training", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2024-01-23", "completion_date": "2025-03-03", "has_results": true, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-11-10T07:09:07.244Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05662306" } ] }